New FDA recommendations support next-generation sequencing-based safety evaluation of off-target editing for personalised gene therapies. (opens in new tab)

FDA draft guidance highlights next-generation sequencing approaches for evaluating off-target effects and genomic integrity in genome editing therapies, supporting safer gene therapy development and regulatory submissions...